Acute Myeloid Leukemia: Updates on Diagnosis and Novel Management Strategies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 25 March 2026 | Viewed by 10
Special Issue Editor
2. Clinic of Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia
Interests: acute myeloblastic leukemia; clinical hematology; diagnostics; prognosis; therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is a clonal disease that occurs due to a block in the maturation of stem cells of the myeloid lineage, their enormous proliferation, and the suppression of apoptosis. The most common cause is the activation or inactivation of certain genes due to various cytogenetic/molecular changes, usually chromosomal translocations, deletions, or other genetic or epigenetic disorders. The incidence of AML ranges from 3.7 to 4.3 per 100,000 population per year.
A full diagnosis of AML includes both the morphological/cytochemical/immunophenotypic and the cytogenetic/molecular definition of the disease, according to the recommendations of the ELN working group from 2022. The most important prognostic parameters in AML are the cytogenetic/molecular findings.
Intensive therapy is reserved for patients under the age of 65 without comorbidities and includes chemotherapy or allogeneic bone marrow transplantation, depending on the disease markers, as well as targeted therapy.
Due to advanced age, other comorbidities, and a higher frequency of unfavorable cytogenetic characteristics, elderly patients are often not suitable for intensive treatment. As a result, in this population, chemotherapy is applied in reduced doses, as well as an inhibitor of the anti-apoptotic bcl-2 protein and hypomethylating agents.
There are numerous challenges to overcome when treating AML patients: it is a disease with a median diagnosis of 67 to 75 years, and patients may have various comorbidities. The solution is an individualized therapeutic approach. A significant problem in AML is the high rate of relapse, as well as patients developing resistance to treatment. The application of innovative therapy and the inclusion of these patients in various clinical trials are of great importance.
For this Special Issue, we invite the submission of primary research articles and comprehensive reviews that address key aspects of diagnosis, clinical management, and prognostic assessment in acute myeloid leukemia.
Prof. Dr. Ana Vidović
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloblastic leukemia
- diagnosis
- prognosis
- intensive chemotherapy
- target therapy
- allogeneic stem cell transplantation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
